SCHEMBL319692

SCHEMBL319692

CC[C@]1(NC(=O)OC(C)(C)C)CCCNC1=O

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.35
PPIA P62937 1/20 0.34
CCR2 P41597 4/20 0.33
GAA P10253 2/20 0.33
P2RX7 Q99572 1/20 0.32
ALDH1A1 P00352 2/20 0.31
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
GHSR Q92847 1/20 0.31
DRD2 P14416 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
CTSK P43235 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318739 0.80 CCR2 (0.35) CCR2GRIN1GRIN2A
SCHEMBL29547310 0.80 CRBN (0.36) CTSLPPIAGAAALDH1A1KMT2A
SCHEMBL14019259 0.79 GAA (0.35) CCR2GAAP2RX7KMT2AMEN1
SCHEMBL7378722 0.77 CTSL (0.39) CTSLCTSK
SCHEMBL319130 0.76 PPIA (0.33) CTSLPPIAGAAP2RX7NFKB1
SCHEMBL7376052 0.76 CTSL (0.36) CTSLPPIAGAANFKB1NFKB2
SCHEMBL318195 0.76 CTSL (0.33) CTSLGAAP2RX7KMT2AMEN1
SCHEMBL18592856 0.76 GAA (0.33) GAAP2RX7KMT2AMEN1SMN1; SMN2
SCHEMBL7394465 0.73 HPGDS (0.40) CTSLGAAP2RX7KMT2AMEN1
SCHEMBL26670511 0.71 POLB (0.40) CTSLGAAALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585447-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2013-05-01 EP disclosed
WO-2012006055-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-12 WO disclosed